<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Press Releases

Jump to a page: News Media Kit

Biodesix Announces Pricing of Initial Public Offering

Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share.

Biodesix Announces Data from Three Studies on Lung Nodule Diagnosis and Management to be Shared at CHEST Annual Meeting 2020

Data presented at the American College of Chest Physicians (CHEST) annual meeting, demonstrate the value of the Nodify Lung™ testing strategy and confirm previously reported performance of the Nodify XL2® and Nodify CDT™ tests.

Big Ten Conference Partners with Biodesix, Inc. and Quidel Corporation

The Big Ten Conference has entered into strategic partnerships with Biodesix, Inc., a leading diagnostic company with a focus on lung disease, and Quidel Corporation, the manufacturer of the FDA-authorized SOFIA 2 SARS rapid antigen test.

ALCMI and Biodesix Initiate Prospective Study to Predict Overall Survival Using Checkpoint Immunotherapy for Front-Line Lung Cancer in Patients with High PDL1 Expression

Addario Lung Cancer Medical Institute (ALCMI) and Biodesix, Inc. today announced they will begin an observational study to prospectively evaluate the clinical utility of biomarkers.

Biodesix to Provide COVID-19 Testing for Colorado State University Campus

Biodesix, Inc. today announced plans to provide COVID-19 ddPCR diagnostic testing for Colorado State University (CSU) as students return to campus for the fall term, which begins August 24.

Biodesix Appoints Jean Franchi and Hany Massarany to Board of Directors

Biodesix today announced the appointment of Jean Franchi and Hany Massarany to the company’s board of directors. Learn more!

Biodesix Pipeline Test Identifies Patients Who Are Likely to Respond to Immune Checkpoint Inhibitors

In the retrospective study, mass spectrometry-based proteomic analysis was performed on pretreatment sera derived from advanced NSCLC patients who were treated with nivolumab as part of routine clinical care.

Major League Lacrosse Partners with Biodesix

Major League Lacrosse (MLL) today announced a partnership with Biodesix, Inc., whereby Biodesix will be the exclusive provider of COVID-19 testing for the upcoming 2020 MLL season.

Biodesix Launches COVID-19 WorkSafe™ Employer Testing Program

Biodesix has launched the Biodesix WorkSafe™ Program, a customized return to work service for employers. Learn more about the testing program.

Biodesix Presents Numerous Research Findings at ATS, ASCO, and AACR Virtual Conferences

The data from these abstracts will be presented as e-posters at the virtual annual meetings of the American Thoracic Society (ATS), American Society of Clinical Oncology (ASCO), and American Association for Cancer Research (AACR).

1 2 3 4 5 6 7 8 9 Last